Amag Pharmaceuticals (AMAG) Close To Confirming A Bullish Trend After A Two Months Pause

Amag Pharmaceuticals (NASDAQ: AMAG) has gained by 15% after a gap-up opening on Monday. The pharmaceuticals manufacturer Amag Pharmaceuticals (AMAG) said sales of its anemia drug ferumoxytol has aggregated to at least $12 million in Q4 of the fiscal.

The 15% gain recorded by Amag Pharmaceuticals (AMAG) has taken the stock past its 200 day moving average after a gap of two months. The high volumes on Amag Pharmaceuticals (AMAG) recorded till mid-day trading confirm the possibilities that the stock may again move into a bullish zone.